NEKTAR THERAPEUTICS
For the period ended Sep 30, 2025. Filed Nov 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 7, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
Except as so indicated in Exhibit 32.1, the following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.
| Exhibit Number | Description of Documents |
| 3.1(1) | Certificate of Incorporation of Inhale Therapeutic Systems (Delaware), Inc. |
| 3.2(2) | Certificate of Amendment of the Amended Certificate of Incorporation of Inhale Therapeutic Systems, Inc. |
| 3.3(3) | Certificate of Ownership and Merger of Nektar Therapeutics. |
| 3.4(4) | Certificate of Ownership and Merger of Nektar Therapeutics AL, Corporation with and into Nektar Therapeutics. |
| 3.5(5) | Certificate of Amendment to the Amended Certificate of Incorporation of Nektar Therapeutics |
| 3.6(6) | Certificate of Amendment to the Amended Certificate of Incorporation of Nektar Therapeutics |
| 3.5(7) | Amended and Restated Bylaws of Nektar Therapeutics. |
| 10.1(8) | Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan, as amended++ |
| 31.1(8) | Certification of Nektar Therapeutics’ principal executive officer required by Rule 13a-14(a) or Rule 15d-14(a). |
| 31.2(8) | Certification of Nektar Therapeutics’ principal financial officer required by Rule 13a-14(a) or Rule 15d-14(a). |
| 32.1* | Section 1350 Certifications. |
| 101.SCH(8) | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents. |
| 101.INS(8) | Inline XBRL Instance Document-the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document. |
| 104(8) | Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101). |
Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics’ Quarterly Report on Form 10-Q, for the quarter ended June 30, 1998.
Incorporated by reference to Exhibit 3.3 to Nektar Therapeutics’ Quarterly Report on Form 10-Q, for the quarter ended June 30, 2000.
Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics’ Current Report on Form 8-K, filed with the SEC on January 23, 2003.
Incorporated by reference to Exhibit 3.6 to Nektar Therapeutics’ Annual Report on Form 10-K, for the year ended December 31, 2009.
Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics’ Current Report on Form 8-K, filed with the SEC on June 6, 2025.
Incorporated by reference to Exhibit 3.12 to Nektar Therapeutics’ Current Report on Form 8-K, filed with the SEC on June 6, 2025.
Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics’ Current Report on Form 8-K, filed with the SEC on December 21, 2020.
Filed herewith.
- Exhibit 32.1 is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange Act, except as otherwise stated in such filing.
++ Management contract or compensatory plan or arrangement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.